{"protocolSection":{"identificationModule":{"nctId":"NCT03596450","orgStudyIdInfo":{"id":"NN9535-4416"},"secondaryIdInfos":[{"id":"U1111-1207-6474","type":"OTHER","domain":"World Health Organization (WHO)"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial","officialTitle":"Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial"},"statusModule":{"statusVerifiedDate":"2026-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-07-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-06-09","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-09","type":"ACTUAL"},"studyFirstSubmitDate":"2018-07-11","studyFirstSubmitQcDate":"2018-07-11","studyFirstPostDateStruct":{"date":"2018-07-23","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-06-09","resultsFirstSubmitQcDate":"2023-07-21","resultsFirstPostDateStruct":{"date":"2023-08-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-09-07","lastUpdatePostDateStruct":{"date":"2026-09-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1278,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","description":"Participants will receive semaglutide subcutaneously (s.c.) in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.","interventionNames":["Drug: Semaglutide"]},{"label":"Standard of care","type":"ACTIVE_COMPARATOR","description":"Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.","interventionNames":["Drug: Standard of care"]}],"interventions":[{"type":"DRUG","name":"Semaglutide","description":"Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.","armGroupLabels":["Semaglutide"]},{"type":"DRUG","name":"Standard of care","description":"Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.","armGroupLabels":["Standard of care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0 % (53 mmol/mol) at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0 % at year 1; No: number of participants who did not achieve HbA1c less than 7.0 % at year 1.","timeFrame":"At year 1"}],"secondaryOutcomes":[{"measure":"Change in HbA1c (Percentage-point [%-Point]) From Baseline to Year 1","description":"Change in HbA1c from baseline to year 1 is presented in %-point.","timeFrame":"Baseline (less than or equal to 90 days prior to randomization at week 0), year 1"},{"measure":"Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0% (53 Millimoles Per Mole [mmol/Mol]) at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0 % (53 mmol/mol) at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0 % at year 2; No: number of participants who did not achieve HbA1c less than 7.0 % at year 2.","timeFrame":"At year 2"},{"measure":"Change in HbA1c (Percentage-point [%-Point]) From Baseline to Year 2","description":"Change in HbA1c from baseline to year 2 is presented in percentage-point.","timeFrame":"Baseline (less than or equal to 90 days prior to randomization at week 0), year 2"},{"measure":"Number of Participants Who Attained Individualized HbA1c Target at Year 1 (Yes/No)","description":"Number of participants who attained individualized HbA1c target at year 1 is presented. Study physicians set and documented an individualized HbA1c target for participants prior to randomization based on their clinical judgement and knowledge of the participant. Yes: number of participants who achieved individualized HbA1c target attained at year 1; No: number of participants who did not achieve individualized HbA1c target attained at year 1","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) or At Least 1% Point Improvement in HbA1c Compared to Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) or at least 1% point improvement in HbA1c compared to baseline at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 1; No: number of participants who did not achieve HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 1","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c target attainment per HEDIS criteria (less than 8.0% if age ≥ 65 years or with defined comorbidities, otherwise less than 7.0%) at year 1 is presented. Yes: Number of participants who achieved HbA1c target attainment per HEDIS criteria at year 1; No: Number of participants who did not achieve HbA1c target attainment per HEDIS criteria at year 1","timeFrame":"At year 1"},{"measure":"Change in Body Weight (in Pounds) From Baseline to Year 1","description":"Change in body weight (in pounds) from baseline to year 1 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Percentage Change in Body Weight From Baseline to Year 1","description":"Percentage change in body weight from baseline to year 1 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change in Systolic Blood Pressure (SBP) From Baseline to Year 1","description":"Change in SBP from baseline to year 1 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change in Diastolic Blood Pressure (DBP) From Baseline to Year 1","description":"Change in DBP from baseline to year 1 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Time to First Study Drug Discontinuation During 2 Years","description":"Time to first study drug discontinuation during 2 years is presented. First study drug discontinuation=date of the first time a patient is not taking study drug as defined.","timeFrame":"Week 0 to year 2"},{"measure":"Time to First Treatment Intensification (Add-on) or Change (Switch) After Randomization During 2 Years","description":"Time to first treatment intensification (add-on) or change (switch) after randomization during 2 years is presented.","timeFrame":"Week 0 to year 2"},{"measure":"Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence for the First Year of the Study","description":"Percentage of MPR for study drug medication adherence for the first year of the study is presented. Medication adherence referred to a participant's conformance to the provider's recommendation with respect to timing, dosage, and frequency of medication taken during the prescribed length of time. The MPR was used to assess adherence. MPR was calculated as follows: MPR (%) = Sum of days supply for all prescription fills\\*100/Total number of days in time period. MPR was capped at 100%. MPR was calculated from pharmacy claims data and irrespective of adherence to randomized treatment or changes to antidiabetic treatment.","timeFrame":"Week 0 to year 1"},{"measure":"Number of Hypoglycemic Episodes Leading to an Inpatient Admission or Emergency Room (ER) Encounter From Baseline to Year 2","description":"Number of hypoglycemic episodes leading to an inpatient admission or emergency room (ER) encounter from baseline to year 2 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Total Treatment Satisfaction Score Measured at Year 1","description":"DTSQc total treatment satisfaction score measured at year 1 is presented. The DTSQc provides a measure of how satisfied participants are with their current diabetes treatment compared with previous treatment. It consists of 8 questions, which are to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change. Six questions are summed to produce a total treatment satisfaction score. The remaining two questions concern perceived frequency of hyperglycemia and perceived frequency of hypoglycemia, respectively. The DTSQc total treatment satisfaction score ranges from -18 to +18, with higher scores associated with greater treatment satisfaction.","timeFrame":"At year 1"},{"measure":"DTSQc, Total Treatment Satisfaction Score Measured at Year 2","description":"DTSQc total treatment satisfaction score measured at year 2 is presented. The DTSQc provides a measure of how satisfied participants are with their current diabetes treatment compared with previous treatment. It consists of 8 questions, which are to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change. Six questions are summed to produce a total treatment satisfaction score. The remaining two questions concern perceived frequency of hyperglycemia and perceived frequency of hypoglycemia, respectively. The DTSQc total treatment satisfaction score ranges from -18 to +18, with higher scores associated with greater treatment satisfaction.","timeFrame":"At year 2"},{"measure":"Change From Baseline in Short Form 12-Item Version 2 Survey (SF-12 v2), Physical Component Summary (PCS-12) Score at Year 1","description":"Change from baseline in SF-12 v2, PCS-12 score at year 1 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change From Baseline in SF-12 v2, PCS-12 Score at Year 2","description":"Change from baseline in SF-12 v2, PCS-12 score at year 2 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change From Baseline in SF-12 v2, Mental Component Summary (MCS-12) Score at Year 1","description":"Change from baseline in SF-12 v2, MCS-12 score at year 1 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: PCS Score and MCS Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change From Baseline in SF-12 v2, MCS-12 Score at Year 2","description":"Change from baseline in SF-12 v2, MCS-12 score at year 2 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: PCS Score and MCS Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change From Baseline in Work Productivity and Activity Impairment, General Health Questionnaire (WPAI-GH) Absenteeism (Work Time Missed) Score at Year 1","description":"Change from baseline in WPAI-GH Absenteeism (work time missed) score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change From Baseline in WPAI-GH Absenteeism (Work Time Missed) Score at Year 2","description":"Change from baseline in WPAI-GH Absenteeism (work time missed) score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change From Baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) Score at Year 1","description":"Change from baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change From Baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) Score at Year 2","description":"Change from baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change From Baseline in WPAI-GH Work Productivity Loss (Overall Work Impairment/Absenteeism Plus Presenteeism) Score at Year 1","description":"Change from baseline in WPAI-GH work productivity loss (overall work impairment/absenteeism plus presenteeism) score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change From Baseline in WPAI-GH Work Productivity Loss (Overall Work Impairment/Absenteeism Plus Presenteeism) Score at Year 2","description":"Change from baseline in WPAI-GH work productivity loss (overall work impairment/absenteeism plus presenteeism) score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change From Baseline in WPAI-GH Activity Impairment Score at Year 1","description":"Change from baseline in WPAI-GH activity impairment score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1"},{"measure":"Change From Baseline in WPAI-GH Activity Impairment Score at Year 2","description":"Change from baseline in WPAI-GH activity impairment score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"All Cause Healthcare Resource Utilization (HCRU): Mean Number of Inpatient Admissions Per Participant From Baseline to Year 2","description":"All cause healthcare resource utilization - mean number of inpatient admissions per participant from baseline to year 2 is presented.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Mean Cumulative Length of Stay for Inpatient Admissions Per Participant From Baseline to Year 2","description":"All cause HCRU - mean cumulative length of stay for inpatient admissions per participant from baseline to year 2 is presented. Cumulative inpatient length of stay is the sum of the length of stay of all inpatient admissions a participant experiences from baseline to year 2.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Mean Number of Emergency Room (ER) Encounters Per Participant From Baseline to Year 2","description":"All cause HCRU - mean number of emergency room (ER) encounters per participant from baseline to year 2 is presented.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Mean Number of Outpatient Encounters Per Participant From Baseline to Year 2","description":"All cause HCRU - mean number of outpatient encounters per participant from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Mean Number of Medication Visits Per Participant From Baseline to Year 2","description":"All cause HCRU - mean number of medication visits per participant from baseline to year 2 is presented.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Number of Participants With Inpatient Admission (Yes/No) From Baseline to Year 2","description":"All cause HCRU - number of participants with inpatient admission from baseline to year 2 is presented. Yes: number of participants who experienced inpatient admission; no: number of participants who did not experience inpatient admission.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Number of Participants With ER Encounter (Yes/No) From Baseline to Year 2","description":"All cause HCRU - number of participants with ER encounter from baseline to year 2 is presented. Yes: number of participants who experienced ER Encounter; no: number of participants who did not experience ER Encounter.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"All Cause HCRU: Number of Participants With Outpatient Encounter (Yes/No) From Baseline to Year 2","description":"All cause HCRU - number of participants with outpatient encounter from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code. Yes: number of participants who experienced outpatient encounter; no: number of participants who did not experience outpatient encounter.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Mean Number of Diabetes Related Inpatient Admissions Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related inpatient admissions per participant from baseline to year 2 is presented.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Mean Cumulative Length of Stay for Diabetes Related Inpatient Admissions Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean cumulative length of stay for diabetes related inpatient admissions per participant from baseline to year 2 is presented. Cumulative inpatient length of stay is the sum of the length of stay of all diabetes related inpatient admissions a participant experiences from baseline to year 2.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Mean Number of Diabetes Related ER Encounters Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related ER encounters per participant from baseline to year 2 is presented.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Mean Number of Diabetes Related Outpatient Encounters Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related outpatient encounters per participant from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Mean Number of Diabetes Related Medication Visits Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related medication visits per participant from baseline to year 2 is presented.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Number of Participants With Diabetes Related Inpatient Admission (Yes/No) From Baseline to Year 2","description":"Diabeted related HCRU - number of participants with diabetes related inpatient admission from baseline to year 2 is presented. Yes: number of participants who experienced diabetes related inpatient admission; no: number of participants who did not experience diabetes related inpatient admission.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Number of Participants With Diabetes Related ER Encounter (Yes/No) From Baseline to Year 2","description":"Diabeted related HCRU - number of participants with diabeted related ER encounter from baseline to year 2 is presented. Yes: number of participants who experienced diabeted related ER encounter; no: number of participants who did not experience diabeted related ER encounter.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Diabetes Related HCRU: Number of Participants With Diabetes Related Outpatient Encounter (Yes/No) From Baseline to Year 2","description":"Diabeted related HCRU - number of participants with diabeted related outpatient encounter from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code. Yes: number of participants who experienced diabeted related outpatient encounter; no: number of participants who did not experience diabeted related outpatient encounter.","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2"},{"measure":"Number of Participants Who Attained Individualized HbA1c Target at Year 2 (Yes/No)","description":"Number of participants who attained individualized HbA1c target at year 2 is presented. Study physicians set and documented an individualized HbA1c target for participants prior to randomization based on their clinical judgement and knowledge of the participant. Yes: number of participants who achieved individualized HbA1c target attained at year 2; No: number of participants who did not achieve individualized HbA1c target attained at year 2","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) or At Least 1% Point Improvement in HbA1c Compared to Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) or at least 1% point improvement in HbA1c compared to baseline at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 2; No: number of participants who did not achieve HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 2.","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1 is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 1.","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2 is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 2.","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) and No Further Antidiabetic Medication Intensification After Randomization at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 1; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 1.","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) and No Further Antidiabetic Medication Intensification After Randomization at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 2; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 2.","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c target attainment per HEDIS criteria (less than 8.0% if age ≥ 65 years or with defined comorbidities, otherwise less than 7.0%) at year 2 is presented. Yes: Number of participants who achieved HbA1c target attainment per HEDIS criteria at year 2; No: Number of participants who did not achieve HbA1c target attainment per HEDIS criteria at year 2.","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) at Year 1 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline.","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) at Year 2 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline.","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 1 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 2 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline.","timeFrame":"At year 2"},{"measure":"Percentage Change in Body Weight From Baseline to Year 2","description":"Percentage change in body weight from baseline to year 2 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change in Body Weight (in Pounds) From Baseline to Year 2","description":"Change in body weight (in pounds) from baseline to year 2 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change in Systolic Blood Pressure (SBP) From Baseline to Year 2","description":"Change in SBP from baseline to year 2 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Change in Diastolic Blood Pressure (DBP) From Baseline to Year 2","description":"Change in DBP from baseline to year 2 is presented.","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2"},{"measure":"Number of Participants With Reported Hypoglycemia Leading to Inpatient Admission or ER Encounter During Year 1 (Yes/No)","description":"Number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 1 is presented. Yes: number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 1; No: number of participants who did not report hypoglycemia leading to inpatient admission or ER encounter during year 1.","timeFrame":"Week 0 to year 1"},{"measure":"Number of Participants With Reported Hypoglycemia Leading to Inpatient Admission or ER Encounter During Year 2 (Yes/No)","description":"Number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 2 is presented. Yes: number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 2; No: number of participants who did not report hypoglycemia leading to inpatient admission or ER encounter during year 2.","timeFrame":"Week 0 to year 2"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and Body Weight Loss of ≥ 5% Versus Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 1; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 1","timeFrame":"At year 1"},{"measure":"Number of Participants With Absolute HbA1c Reduction of ≥ 0.5% Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and a Body Weight Loss of ≥ 5% Versus Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 1 is presented. Yes: number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 1; No: number of participants who did not achieve absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 1.","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and Body Weight Loss of ≥ 5% Versus Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 2; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 2.","timeFrame":"At year 2"},{"measure":"Number of Participants With Absolute HbA1c Reduction of ≥ 0.5% Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and a Body Weight Loss of ≥ 5% Versus Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 2 is presented. Yes: number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 2; No: number of participants who did not achieve absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 2.","timeFrame":"At year 2"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and No Body Weight Gain Versus Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 1; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 1.","timeFrame":"At year 1"},{"measure":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and No Body Weight Gain Versus Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 2; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 2.","timeFrame":"At year 2"},{"measure":"Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence For The Two Years of The Study","description":"Percentage of MPR for study drug medication adherence for the two years of the study is presented. Medication adherence referred to a participant's conformance to the provider's recommendation with respect to timing, dosage, and frequency of medication taken during the prescribed length of time. The MPR was used to assess adherence. MPR was calculated as follows: MPR (%) = Sum of days supply for all prescription fills\\*100/Total number of days in time period. MPR was capped at 100%. MPR was calculated from pharmacy claims data and irrespective of adherence to randomized treatment or changes to antidiabetic treatment.","timeFrame":"Week 0 to year 2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:-\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.\n* Male or female, age 18 years or older at the time of signing informed consent.\n* Type 2 diabetes mellitus diagnosis.\n* Treatment with either 1 or 2 oral antidiabetic medications.\n* Current member of a commercial or Medicare health plan with pharmacy benefits.\n* Recorded HbAlc value within the last 90 days prior to randomization.\n* Further intensification with an additional antidiabetic oral or injectable medication is indicated to achieve glycemic target at the discretion of the study physician according to approved labelling.\n\nExclusion Criteria:\n\n* Previous randomization in this study\n* Treatment with more than 2 oral antidiabetic medications, oral semaglutide, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is prior insulin treatment for gestational diabetes.\n* Contraindications to semaglutide according to the Food and Drug Administration approved label.\n* Female who is pregnant, breastfeeding or intends to become pregnant\n* Participation in another clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Reporting Anchor and Disclosure (1452)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"American Clinical Trials","city":"Buena Park","state":"California","zip":"90620","country":"United States","geoPoint":{"lat":33.86751,"lon":-117.99812}},{"facility":"Endocrine Specialty Consultant Inc.","city":"Burbank","state":"California","zip":"91505","country":"United States","geoPoint":{"lat":34.18084,"lon":-118.30897}},{"facility":"FDRC","city":"Costa Mesa","state":"California","zip":"92627","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"Bay Area Clinical Research","city":"Dublin","state":"California","zip":"94568","country":"United States","geoPoint":{"lat":37.70215,"lon":-121.93579}},{"facility":"Providence Medical Foundation","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"SC Clinical Research, Inc.","city":"Garden Grove","state":"California","zip":"92844","country":"United States","geoPoint":{"lat":33.77391,"lon":-117.94145}},{"facility":"SCKE Odyssey Medical Group","city":"Laguna Hills","state":"California","zip":"92653","country":"United States","geoPoint":{"lat":33.61252,"lon":-117.71283}},{"facility":"New Hope Consulting & Clinical Trials","city":"Lancaster","state":"California","zip":"93534","country":"United States","geoPoint":{"lat":34.69804,"lon":-118.13674}},{"facility":"OM Research LLC","city":"Lancaster","state":"California","zip":"93534","country":"United States","geoPoint":{"lat":34.69804,"lon":-118.13674}},{"facility":"Torrance Clin Res Inst, Inc.","city":"Lomita","state":"California","zip":"90717","country":"United States","geoPoint":{"lat":33.79224,"lon":-118.31507}},{"facility":"West Coast Endocrine, Inc.","city":"Long Beach","state":"California","zip":"90815","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Pacific Clinical Studies","city":"Los Alamitos","state":"California","zip":"90720","country":"United States","geoPoint":{"lat":33.80307,"lon":-118.07256}},{"facility":"Angel City Research","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"University of Californ LA-UCLA","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Patel, Rahul","city":"Manteca","state":"California","zip":"95336","country":"United States","geoPoint":{"lat":37.79743,"lon":-121.21605}},{"facility":"Pacific Medical Center","city":"Milpitas","state":"California","zip":"95035","country":"United States","geoPoint":{"lat":37.42827,"lon":-121.90662}},{"facility":"Facey Medical Foundation","city":"Mission Hills","state":"California","zip":"91345","country":"United States","geoPoint":{"lat":34.68609,"lon":-120.43683}},{"facility":"Monterey Endocrine & Diabetes Institute, Inc","city":"Monterey","state":"California","zip":"93940","country":"United States","geoPoint":{"lat":36.60024,"lon":-121.89468}},{"facility":"Do-Eun Lee","city":"Napa","state":"California","zip":"94558","country":"United States","geoPoint":{"lat":38.29714,"lon":-122.28553}},{"facility":"Charles Andrews, MD","city":"Newport Beach","state":"California","zip":"92660","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Hoag Medical Group","city":"Newport Beach","state":"California","zip":"92663","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Adam B. Sherman D O Professional Corp.","city":"Oxnard","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":34.1975,"lon":-119.17705}},{"facility":"Format Medical Research","city":"Oxnard","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":34.1975,"lon":-119.17705}},{"facility":"Stanford Univ School of Med","city":"Palo Alto","state":"California","zip":"94304","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Posada, Juan","city":"San Jose","state":"California","zip":"95116","country":"United States","geoPoint":{"lat":37.33939,"lon":-121.89496}},{"facility":"Joselito C Cabaccan, MD","city":"San Jose","state":"California","zip":"95148","country":"United States","geoPoint":{"lat":37.33939,"lon":-121.89496}},{"facility":"Care Access Research Santa Clarita","city":"Santa Clarita","state":"California","zip":"91321","country":"United States","geoPoint":{"lat":34.39166,"lon":-118.54259}},{"facility":"Premier Medical Center, Inc.","city":"Toluca Lake","state":"California","zip":"91602","country":"United States","geoPoint":{"lat":34.15206,"lon":-118.35719}},{"facility":"Adnab Research/Prestige Care Physician","city":"Torrance","state":"California","zip":"90505","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"Altura Centers For Health","city":"Tulare","state":"California","zip":"93274","country":"United States","geoPoint":{"lat":36.20773,"lon":-119.34734}},{"facility":"Tariq Javed, MD Inc.","city":"Visalia","state":"California","zip":"93291","country":"United States","geoPoint":{"lat":36.33023,"lon":-119.29206}},{"facility":"Endocrinology & Diabetes Specialists","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"PIH Health Physicians Endocrinology","city":"Whittier","state":"California","zip":"90606","country":"United States","geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"Optumcare Clinical Trials,LLC-Golden","city":"Colorado Springs","state":"Colorado","zip":"80906","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Delta Waves, Inc.","city":"Colorado Springs","state":"Colorado","zip":"80918","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"University of Colorado Hospital","city":"Denver","state":"Colorado","zip":"80220","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Denver Endocrinology Diabetes and Thyroid Center","city":"Englewood","state":"Colorado","zip":"80113","country":"United States","geoPoint":{"lat":39.64777,"lon":-104.98776}},{"facility":"ProHealth Physicians/OptumCare","city":"Bristol","state":"Connecticut","zip":"06010","country":"United States","geoPoint":{"lat":41.67176,"lon":-72.94927}},{"facility":"Western Connecticut Health Network_Danbury","city":"Danbury","state":"Connecticut","zip":"06810","country":"United States","geoPoint":{"lat":41.39482,"lon":-73.45401}},{"facility":"Endocrine Associates of Connecticut","city":"Hamden","state":"Connecticut","zip":"06517","country":"United States","geoPoint":{"lat":41.39593,"lon":-72.89677}},{"facility":"Ismail Tarkhan MD","city":"Milford","state":"Connecticut","zip":"06460","country":"United States","geoPoint":{"lat":41.22232,"lon":-73.0565}},{"facility":"Steven L. Saunders MD LLC","city":"Milford","state":"Connecticut","zip":"06460","country":"United States","geoPoint":{"lat":41.22232,"lon":-73.0565}},{"facility":"Westside Center For Clinical Research","city":"Jacksonville","state":"Florida","zip":"32205","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"The Kaufmann Clinic, Inc.","city":"Atlanta","state":"Georgia","zip":"30106","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Primary Care Research","city":"Atlanta","state":"Georgia","zip":"30312","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Southern Family Medical Center","city":"Augusta","state":"Georgia","zip":"04915","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"River Birch Research Alliance, LLC","city":"Blue Ridge","state":"Georgia","zip":"30513","country":"United States","geoPoint":{"lat":34.86397,"lon":-84.32409}},{"facility":"Gwinnett Research Insti/Buford Family Pract Urgent Care Ctr","city":"Buford","state":"Georgia","zip":"30519","country":"United States","geoPoint":{"lat":34.12066,"lon":-84.00435}},{"facility":"Centricity Research","city":"Columbus","state":"Georgia","zip":"31904","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Medical Care of LaGrange","city":"La Grange","state":"Georgia","zip":"30240","country":"United States","geoPoint":{"lat":33.03929,"lon":-85.03133}},{"facility":"Beaver Ruin Primary Care","city":"Lilburn","state":"Georgia","zip":"30047","country":"United States","geoPoint":{"lat":33.8901,"lon":-84.14297}},{"facility":"Privia Medical Group of Georgia LLC","city":"Locust Grove","state":"Georgia","zip":"30248","country":"United States","geoPoint":{"lat":33.34595,"lon":-84.10908}},{"facility":"DC Research Works","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Urban Family Practice Assoc","city":"Marietta","state":"Georgia","zip":"30067","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Atlanta Center for Clinical Research","city":"Roswell","state":"Georgia","zip":"30075","country":"United States","geoPoint":{"lat":34.02316,"lon":-84.36159}},{"facility":"Sandersville Family Practice","city":"Sandersville","state":"Georgia","zip":"31082","country":"United States","geoPoint":{"lat":32.98154,"lon":-82.81014}},{"facility":"Meridian Clin Res, LLC","city":"Savannah","state":"Georgia","zip":"31406","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Family Health Care Center","city":"Statesboro","state":"Georgia","zip":"30461","country":"United States","geoPoint":{"lat":32.44879,"lon":-81.78317}},{"facility":"Eagles Landing Diabetes/Endocrinology","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"First Medical Research Center","city":"Stone Mountain","state":"Georgia","zip":"30083","country":"United States","geoPoint":{"lat":33.80816,"lon":-84.1702}},{"facility":"Herman Clinical Research LLC","city":"Suwanee","state":"Georgia","zip":"30024","country":"United States","geoPoint":{"lat":34.05149,"lon":-84.0713}},{"facility":"Sugarloaf Medical, PC","city":"Suwanee","state":"Georgia","zip":"30024","country":"United States","geoPoint":{"lat":34.05149,"lon":-84.0713}},{"facility":"East Georgia Healthcare Center Inc","city":"Swainsboro","state":"Georgia","zip":"30401","country":"United States","geoPoint":{"lat":32.59739,"lon":-82.33374}},{"facility":"Coastal Care Medical Clinic","city":"Waycross","state":"Georgia","zip":"31501","country":"United States","geoPoint":{"lat":31.21368,"lon":-82.3557}},{"facility":"Solaris Clinical Research","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"St. Vincent Research Institute","city":"Anderson","state":"Indiana","zip":"46016","country":"United States","geoPoint":{"lat":40.10532,"lon":-85.68025}},{"facility":"American Health Network of Indiana, LLC_Avon_0","city":"Avon","state":"Indiana","zip":"46123","country":"United States","geoPoint":{"lat":39.76282,"lon":-86.39972}},{"facility":"Tom H. Jones","city":"Avon","state":"Indiana","zip":"46123","country":"United States","geoPoint":{"lat":39.76282,"lon":-86.39972}},{"facility":"Adams County Family Physicians","city":"Berne","state":"Indiana","zip":"46711","country":"United States","geoPoint":{"lat":40.65782,"lon":-84.95191}},{"facility":"Deaconess Clinic, Inc.","city":"Evansville","state":"Indiana","zip":"47725","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"Associated Surgeons & Physicians LLC","city":"Fort Wayne","state":"Indiana","zip":"46825","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"American Health Network of IN LLC_Franklin","city":"Franklin","state":"Indiana","zip":"46131","country":"United States","geoPoint":{"lat":39.48061,"lon":-86.05499}},{"facility":"American Health Network of Indiana, LLC_Greenfield","city":"Greenfield","state":"Indiana","zip":"46140","country":"United States","geoPoint":{"lat":39.78504,"lon":-85.76942}},{"facility":"Indiana Internal Medicine Consultants LLC","city":"Greenwood","state":"Indiana","zip":"46143","country":"United States","geoPoint":{"lat":39.61366,"lon":-86.10665}},{"facility":"La Porte County Institute For Clinical Research","city":"Michigan City","state":"Indiana","zip":"46360","country":"United States","geoPoint":{"lat":41.70754,"lon":-86.89503}},{"facility":"Beacon Medical Group Swartz-Weikamp","city":"Mishawaka","state":"Indiana","zip":"46544","country":"United States","geoPoint":{"lat":41.66199,"lon":-86.15862}},{"facility":"Indiana University Health Ball Memorial Hospital","city":"Muncie","state":"Indiana","zip":"47303","country":"United States","geoPoint":{"lat":40.19338,"lon":-85.38636}},{"facility":"American Health Network of IN LLC","city":"Muncie","state":"Indiana","zip":"47304","country":"United States","geoPoint":{"lat":40.19338,"lon":-85.38636}},{"facility":"Elpidio M. Feliciano","city":"Muncie","state":"Indiana","zip":"47304","country":"United States","geoPoint":{"lat":40.19338,"lon":-85.38636}},{"facility":"American Health Network of Indiana, LLC","city":"New Albany","state":"Indiana","zip":"47150","country":"United States","geoPoint":{"lat":38.28562,"lon":-85.82413}},{"facility":"Reid Endocrinology Center","city":"Richmond","state":"Indiana","zip":"47374","country":"United States","geoPoint":{"lat":39.82894,"lon":-84.89024}},{"facility":"Regional Endorine and Diabetes Associates","city":"Ashland","state":"Kentucky","zip":"41101","country":"United States","geoPoint":{"lat":38.47841,"lon":-82.63794}},{"facility":"Tri State Primary Caregrayson Health Park","city":"Ashland","state":"Kentucky","zip":"41101","country":"United States","geoPoint":{"lat":38.47841,"lon":-82.63794}},{"facility":"St Elizabeth Physicians Heart","city":"Covington","state":"Kentucky","zip":"41011","country":"United States","geoPoint":{"lat":39.08367,"lon":-84.50855}},{"facility":"Patel Medical Center","city":"Irvington","state":"Kentucky","zip":"40146","country":"United States","geoPoint":{"lat":37.88034,"lon":-86.28386}},{"facility":"The Endocrine & Diabetes Center","city":"Owensboro","state":"Kentucky","zip":"42303","country":"United States","geoPoint":{"lat":37.77422,"lon":-87.11333}},{"facility":"Paris Family Physicians PLLC","city":"Paris","state":"Kentucky","zip":"40361","country":"United States","geoPoint":{"lat":38.2098,"lon":-84.25299}},{"facility":"Gaurang B. Shah, MD","city":"Richmond","state":"Kentucky","zip":"40475","country":"United States","geoPoint":{"lat":37.74786,"lon":-84.29465}},{"facility":"Versailles Family Medicine","city":"Versailles","state":"Kentucky","zip":"40383","country":"United States","geoPoint":{"lat":38.05258,"lon":-84.72995}},{"facility":"WCMP Family Medicine","city":"Belfast","state":"Maine","zip":"04915","country":"United States","geoPoint":{"lat":44.42591,"lon":-69.00642}},{"facility":"MD Medical Research","city":"Oxon Hill","state":"Maryland","zip":"20745","country":"United States","geoPoint":{"lat":38.80345,"lon":-76.9897}},{"facility":"Tri-County Research, Inc.","city":"Sterling Heights","state":"Michigan","zip":"48310-3503","country":"United States","geoPoint":{"lat":42.58031,"lon":-83.0302}},{"facility":"Diabetes & Endo Specialists Inc","city":"Chesterfield","state":"Missouri","zip":"63017","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"University Of Missouri - Columbia","city":"Columbia","state":"Missouri","zip":"65201","country":"United States","geoPoint":{"lat":38.95171,"lon":-92.33407}},{"facility":"Jefferson City Medical Group, PC","city":"Jefferson City","state":"Missouri","zip":"65109","country":"United States","geoPoint":{"lat":38.5767,"lon":-92.17352}},{"facility":"Trinity Healthcare","city":"Springfield","state":"Missouri","zip":"65803","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Saint Louis University","city":"St Louis","state":"Missouri","zip":"63104","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"South County Endocrinology and Obesity Medicine, LLC","city":"St Louis","state":"Missouri","zip":"63128","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Desert Endocrinology Clinical Research Center","city":"Las Vegas","state":"Nevada","zip":"89117","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Palm Research Center Inc-Vegas","city":"Las Vegas","state":"Nevada","zip":"89148","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Southern New Hampshire Diabete","city":"Nashua","state":"New Hampshire","zip":"03060","country":"United States","geoPoint":{"lat":42.76537,"lon":-71.46757}},{"facility":"AMC Community Endocrinology","city":"Albany","state":"New York","zip":"12203","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Prominis Medical Services PC","city":"Brooklyn","state":"New York","zip":"11221","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Northwell Health Div of Endo","city":"Great Neck","state":"New York","zip":"11021","country":"United States","geoPoint":{"lat":40.80066,"lon":-73.72846}},{"facility":"Advanced Internal Medicine Group","city":"Great Neck","state":"New York","zip":"11023","country":"United States","geoPoint":{"lat":40.80066,"lon":-73.72846}},{"facility":"Smart Medical Research Inc.","city":"Jackson Heights","state":"New York","zip":"11372","country":"United States","geoPoint":{"lat":40.75566,"lon":-73.88541}},{"facility":"Rockcastle Family Endocrinology","city":"Mount Vernon","state":"New York","zip":"40456","country":"United States","geoPoint":{"lat":40.9126,"lon":-73.83708}},{"facility":"NYC Research, Inc.","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"NYU Grossman School of Med","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Elligo Health Research Inc","city":"New York","state":"New York","zip":"10028","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Endocrine Associates of Long Island, PC","city":"Smithtown","state":"New York","zip":"11787","country":"United States","geoPoint":{"lat":40.85593,"lon":-73.20067}},{"facility":"EDOC LLP","city":"Yonkers","state":"New York","zip":"10704","country":"United States","geoPoint":{"lat":40.9304,"lon":-73.89789}},{"facility":"OnSite Clinical Solutions, LLC_Charlotte_0","city":"Charlotte","state":"North Carolina","zip":"28210","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"OnSite Clinical Solutions, LLC_Charlotte","city":"Charlotte","state":"North Carolina","zip":"28277","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Burke Primary Care","city":"Morganton","state":"North Carolina","zip":"28655","country":"United States","geoPoint":{"lat":35.74541,"lon":-81.68482}},{"facility":"Lillestol Research LLC","city":"Fargo","state":"North Dakota","zip":"58104","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Valley Weight Loss Clinic","city":"Fargo","state":"North Dakota","zip":"58104","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Catherine LaRuffa, M.D., Inc.","city":"Blanchester","state":"Ohio","zip":"45107","country":"United States","geoPoint":{"lat":39.29312,"lon":-83.98882}},{"facility":"Diab & Endo Assoc of Stark Co","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Medical Frontiers, LLC","city":"Carlisle","state":"Ohio","zip":"45005","country":"United States","geoPoint":{"lat":39.582,"lon":-84.32022}},{"facility":"University of Cincinnati/UC Health","city":"Cincinnati","state":"Ohio","zip":"45241","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"University Hospitals of Cleveland Case Medical Center","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Central Ohio Clinical Research LLC","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Centricity Research","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Providence Health Partners Ctr","city":"Dayton","state":"Ohio","zip":"45439","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Franklin Family Practice","city":"Franklin","state":"Ohio","zip":"45005","country":"United States","geoPoint":{"lat":39.55895,"lon":-84.30411}},{"facility":"Prestige Clinical Research","city":"Franklin","state":"Ohio","zip":"45005","country":"United States","geoPoint":{"lat":39.55895,"lon":-84.30411}},{"facility":"Albert J Weisbrot","city":"Mason","state":"Ohio","zip":"45040-6815","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Functional Endocrinology","city":"Mason","state":"Ohio","zip":"45040","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Toledo Clinic","city":"Toledo","state":"Ohio","zip":"43623","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"New Venture Medical Research","city":"Wadsworth","state":"Ohio","zip":"44281","country":"United States","geoPoint":{"lat":41.02561,"lon":-81.72985}},{"facility":"Harleysville Medical Associates","city":"Harleysville","state":"Pennsylvania","zip":"19438","country":"United States","geoPoint":{"lat":40.27955,"lon":-75.38712}},{"facility":"Detweiler Family Med","city":"Lansdale","state":"Pennsylvania","zip":"19446-1002","country":"United States","geoPoint":{"lat":40.2415,"lon":-75.28379}},{"facility":"Primary Care Research South, Inc","city":"McMurray","state":"Pennsylvania","zip":"15317","country":"United States","geoPoint":{"lat":40.27785,"lon":-80.08394}},{"facility":"Master Centre for USA","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Preferred Primary Care Physicians_Pittsburgh","city":"Pittsburgh","state":"Pennsylvania","zip":"15236","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Athens Medical Group","city":"Athens","state":"Tennessee","zip":"37303","country":"United States","geoPoint":{"lat":35.44285,"lon":-84.59299}},{"facility":"PMG Research of Bristol","city":"Bristol","state":"Tennessee","zip":"24201","country":"United States","geoPoint":{"lat":36.59511,"lon":-82.18874}},{"facility":"Murphy Research Center","city":"Humboldt","state":"Tennessee","zip":"38343","country":"United States","geoPoint":{"lat":35.81979,"lon":-88.9159}},{"facility":"Ascend Research Centers, Inc.","city":"McMinnville","state":"Tennessee","zip":"37110","country":"United States","geoPoint":{"lat":35.6834,"lon":-85.76998}},{"facility":"Rockwood Medical Clinic","city":"Fort Worth","state":"Texas","zip":"76164","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"TVC Clinical Research","city":"Gonzales","state":"Texas","zip":"78629","country":"United States","geoPoint":{"lat":29.50163,"lon":-97.45249}},{"facility":"PrimeCare Medical Group","city":"Houston","state":"Texas","zip":"77024","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Southwest Urgent Care and Family practice","city":"Houston","state":"Texas","zip":"77081","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Christus Trinity Clinic Hill Country Landa","city":"New Braunfels","state":"Texas","zip":"78130","country":"United States","geoPoint":{"lat":29.703,"lon":-98.12445}},{"facility":"Hill Country Medical Associates","city":"New Braunfels","state":"Texas","zip":"78130","country":"United States","geoPoint":{"lat":29.703,"lon":-98.12445}},{"facility":"HAS Research","city":"San Antonio","state":"Texas","zip":"78240","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Simcare Medical Research, LLC","city":"Sugar Land","state":"Texas","zip":"77478","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Chrysalis Clinical Research","city":"St. George","state":"Utah","zip":"84790","country":"United States","geoPoint":{"lat":37.10415,"lon":-113.58412}},{"facility":"The Endocrinology Group","city":"Arlington","state":"Virginia","zip":"22205","country":"United States","geoPoint":{"lat":38.88101,"lon":-77.10428}},{"facility":"Chatham Family Medical Center","city":"Chatham","state":"Virginia","zip":"24531","country":"United States","geoPoint":{"lat":36.82569,"lon":-79.39808}},{"facility":"Swift Creek Family Care","city":"Colonial Heights","state":"Virginia","zip":"23834","country":"United States","geoPoint":{"lat":37.26804,"lon":-77.40726}},{"facility":"Lawson Family Medicine & Aesthetics","city":"Daleville","state":"Virginia","zip":"23083","country":"United States","geoPoint":{"lat":37.40986,"lon":-79.91254}},{"facility":"Privia Medical Group LLC","city":"Danville","state":"Virginia","zip":"24541","country":"United States","geoPoint":{"lat":36.58597,"lon":-79.39502}},{"facility":"Seven Corners Medical","city":"Falls Church","state":"Virginia","zip":"22044","country":"United States","geoPoint":{"lat":38.88233,"lon":-77.17109}},{"facility":"Courtside Family Medicine PLLC","city":"Gloucester","state":"Virginia","zip":"23061","country":"United States","geoPoint":{"lat":37.41375,"lon":-76.52551}},{"facility":"Hampton Family Practice","city":"Hampton","state":"Virginia","zip":"23666","country":"United States","geoPoint":{"lat":37.02987,"lon":-76.34522}},{"facility":"Hartford Internal Medicine","city":"Hampton","state":"Virginia","zip":"23666","country":"United States","geoPoint":{"lat":37.02987,"lon":-76.34522}},{"facility":"Medical Associates of Central Virginia, Inc.","city":"Lynchburg","state":"Virginia","zip":"24501","country":"United States","geoPoint":{"lat":37.41375,"lon":-79.14225}},{"facility":"Virginia Research Center","city":"Midlothian","state":"Virginia","zip":"23114","country":"United States","geoPoint":{"lat":37.50598,"lon":-77.64916}},{"facility":"C. Lee Ginsburgh","city":"Newport News","state":"Virginia","zip":"23606","country":"United States","geoPoint":{"lat":36.98038,"lon":-76.42975}},{"facility":"York Clinical Research LLC","city":"Norfolk","state":"Virginia","zip":"23504","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Eastern Virginia Medical School","city":"Norfolk","state":"Virginia","zip":"23510","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Clinical Research Partners","city":"North Chesterfield","state":"Virginia","zip":"23235","country":"United States","geoPoint":{"lat":37.38,"lon":-77.59}},{"facility":"Family Medicine Healthcare","city":"Portsmouth","state":"Virginia","zip":"23701","country":"United States","geoPoint":{"lat":36.83543,"lon":-76.29827}},{"facility":"Family Health Clinic","city":"Radford","state":"Virginia","zip":"24141","country":"United States","geoPoint":{"lat":37.13179,"lon":-80.57645}},{"facility":"Dominion Medical Associates","city":"Richmond","state":"Virginia","zip":"23219","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Halifax Internal Medicine","city":"South Boston","state":"Virginia","zip":"24592","country":"United States","geoPoint":{"lat":36.69875,"lon":-78.9014}},{"facility":"Southside Primary Care","city":"South Chesterfield","state":"Virginia","zip":"23803","country":"United States"},{"facility":"Colonial Medical Clinic","city":"South Chesterfield","state":"Virginia","zip":"23834","country":"United States"},{"facility":"Hampton Roads Center for Clinical Research","city":"Suffolk","state":"Virginia","zip":"23435","country":"United States","geoPoint":{"lat":36.72836,"lon":-76.58496}},{"facility":"Endocrinology Consultants","city":"Virginia Beach","state":"Virginia","zip":"23454","country":"United States","geoPoint":{"lat":36.85293,"lon":-75.97799}},{"facility":"Corporation Lane Research Center","city":"Virginia Beach","state":"Virginia","zip":"23462","country":"United States","geoPoint":{"lat":36.85293,"lon":-75.97799}},{"facility":"Piedmont Family Practice PLC","city":"Warrenton","state":"Virginia","zip":"20186","country":"United States","geoPoint":{"lat":38.71345,"lon":-77.79527}},{"facility":"Tidewater Physicians Multispecialty Group","city":"Williamsburg","state":"Virginia","zip":"23188","country":"United States","geoPoint":{"lat":37.2707,"lon":-76.70746}},{"facility":"Family Care of Williamsburg","city":"Williamsburg","state":"Virginia","zip":"49820","country":"United States","geoPoint":{"lat":37.2707,"lon":-76.70746}},{"facility":"Selma Medical Associates","city":"Winchester","state":"Virginia","zip":"22601-3834","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"facility":"St. Vincent Hosp-Prevea Health","city":"Green Bay","state":"Wisconsin","zip":"54303","country":"United States","geoPoint":{"lat":44.51916,"lon":-88.01983}},{"facility":"Ascension Medical Group- Germantown Clinic","city":"Milwaukee","state":"Wisconsin","zip":"53211","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Medical College of Wisconsin & Zablocki VAMC","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Western University Medical Center at WU of Health Sciences","city":"London","state":"Ontario","zip":"N6G 2M1","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}}]},"referencesModule":{"references":[{"pmid":"41093600","type":"DERIVED","citation":"Buse JB, Nordahl Christensen H, Harty BJ, Cziraky MJ, Willey VJ, Skibsted S. Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial. BMJ Open Diabetes Res Care. 2025 Oct 15;13(5):e005161. doi: 10.1136/bmjdrc-2025-005161."},{"pmid":"37137527","type":"DERIVED","citation":"Buse JB, Nordahl Christensen H, Harty BJ, Mitchell J, Soule BP, Zacherle E, Cziraky M, Willey VJ. Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial. BMJ Open Diabetes Res Care. 2023 May;11(3):e003206. doi: 10.1136/bmjdrc-2022-003206."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com","url":"http://novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 1,278 participants were randomized 1:1 to receive either semaglutide or standard of care (SOC).","recruitmentDetails":"The trial was conducted at 138 sites in the United States.","groups":[{"id":"FG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"FG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"644"},{"groupId":"FG001","numSubjects":"634"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"463"},{"groupId":"FG001","numSubjects":"447"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"181"},{"groupId":"FG001","numSubjects":"187"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"26"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"56"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"36"}]},{"type":"Accidentally Randomized","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Other reasons","reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"53"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) included all randomized participants analyzed according to the treatment group to which they were assigned at randomization.","groups":[{"id":"BG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"BG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"644"},{"groupId":"BG001","value":"634"},{"groupId":"BG002","value":"1278"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"644"},{"groupId":"BG001","value":"634"},{"groupId":"BG002","value":"1278"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"57.47","spread":"11.305"},{"groupId":"BG001","value":"57.24","spread":"10.982"},{"groupId":"BG002","value":"57.36","spread":"11.142"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"Gender data for one participant is missing in the Semaglutide arm.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"643"},{"groupId":"BG001","value":"634"},{"groupId":"BG002","value":"1277"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"309"},{"groupId":"BG001","value":"276"},{"groupId":"BG002","value":"585"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"334"},{"groupId":"BG001","value":"358"},{"groupId":"BG002","value":"692"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"644"},{"groupId":"BG001","value":"634"},{"groupId":"BG002","value":"1278"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"114"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"586"},{"groupId":"BG001","value":"577"},{"groupId":"BG002","value":"1163"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"644"},{"groupId":"BG001","value":"634"},{"groupId":"BG002","value":"1278"}]}],"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"517"},{"groupId":"BG001","value":"487"},{"groupId":"BG002","value":"1004"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"189"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]},{"title":"American Indian or Alaska Native, Asian","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"43"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"36"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0 % (53 mmol/mol) at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0 % at year 1; No: number of participants who did not achieve HbA1c less than 7.0 % at year 1.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"430"},{"groupId":"OG001","value":"462"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"226"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"236"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Estimate and p-value are based on logistic regression model with logit link function, treatment as categorical effect, and baseline HbA1c as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"0.033","statisticalMethod":"Regression, Logistic","paramType":"Treatment effect","paramValue":"1.36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.03","ciUpperLimit":"1.79"}]},{"type":"SECONDARY","title":"Change in HbA1c (Percentage-point [%-Point]) From Baseline to Year 1","description":"Change in HbA1c from baseline to year 1 is presented in %-point.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage-point of HbA1c","timeFrame":"Baseline (less than or equal to 90 days prior to randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"430"},{"groupId":"OG001","value":"461"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":"1.669"},{"groupId":"OG001","value":"-1.14","spread":"1.707"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0% (53 Millimoles Per Mole [mmol/Mol]) at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0 % (53 mmol/mol) at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0 % at year 2; No: number of participants who did not achieve HbA1c less than 7.0 % at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"162"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"212"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (Percentage-point [%-Point]) From Baseline to Year 2","description":"Change in HbA1c from baseline to year 2 is presented in percentage-point.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage-point of HbA1c","timeFrame":"Baseline (less than or equal to 90 days prior to randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"373"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.45","spread":"1.723"},{"groupId":"OG001","value":"-0.98","spread":"1.767"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Attained Individualized HbA1c Target at Year 1 (Yes/No)","description":"Number of participants who attained individualized HbA1c target at year 1 is presented. Study physicians set and documented an individualized HbA1c target for participants prior to randomization based on their clinical judgement and knowledge of the participant. Yes: number of participants who achieved individualized HbA1c target attained at year 1; No: number of participants who did not achieve individualized HbA1c target attained at year 1","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"430"},{"groupId":"OG001","value":"462"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"170"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"292"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) or At Least 1% Point Improvement in HbA1c Compared to Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) or at least 1% point improvement in HbA1c compared to baseline at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 1; No: number of participants who did not achieve HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 1","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"430"},{"groupId":"OG001","value":"462"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"301"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"160"}]}]},{"title":"Data missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c target attainment per HEDIS criteria (less than 8.0% if age ≥ 65 years or with defined comorbidities, otherwise less than 7.0%) at year 1 is presented. Yes: Number of participants who achieved HbA1c target attainment per HEDIS criteria at year 1; No: Number of participants who did not achieve HbA1c target attainment per HEDIS criteria at year 1","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"53"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"45"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (in Pounds) From Baseline to Year 1","description":"Change in body weight (in pounds) from baseline to year 1 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Pounds (lbs)","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"458"},{"groupId":"OG001","value":"461"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"21.15"},{"groupId":"OG001","value":"-5.4","spread":"20.70"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Body Weight From Baseline to Year 1","description":"Percentage change in body weight from baseline to year 1 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change in body weight","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"458"},{"groupId":"OG001","value":"461"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.93","spread":"11.092"},{"groupId":"OG001","value":"-2.02","spread":"8.924"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Year 1","description":"Change in SBP from baseline to year 1 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"457"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"16.40"},{"groupId":"OG001","value":"-1.8","spread":"16.34"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure (DBP) From Baseline to Year 1","description":"Change in DBP from baseline to year 1 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"457"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"10.08"},{"groupId":"OG001","value":"-0.9","spread":"9.79"}]}]}]},{"type":"SECONDARY","title":"Time to First Study Drug Discontinuation During 2 Years","description":"Time to first study drug discontinuation during 2 years is presented. First study drug discontinuation=date of the first time a patient is not taking study drug as defined.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Years","timeFrame":"Week 0 to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"634"},{"groupId":"OG001","value":"621"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"0.853"},{"groupId":"OG001","value":"1.54","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Time to First Treatment Intensification (Add-on) or Change (Switch) After Randomization During 2 Years","description":"Time to first treatment intensification (add-on) or change (switch) after randomization during 2 years is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Years","timeFrame":"Week 0 to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"575"},{"groupId":"OG001","value":"550"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"0.731"},{"groupId":"OG001","value":"1.43","spread":"0.742"}]}]}]},{"type":"SECONDARY","title":"Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence for the First Year of the Study","description":"Percentage of MPR for study drug medication adherence for the first year of the study is presented. Medication adherence referred to a participant's conformance to the provider's recommendation with respect to timing, dosage, and frequency of medication taken during the prescribed length of time. The MPR was used to assess adherence. MPR was calculated as follows: MPR (%) = Sum of days supply for all prescription fills\\*100/Total number of days in time period. MPR was capped at 100%. MPR was calculated from pharmacy claims data and irrespective of adherence to randomized treatment or changes to antidiabetic treatment.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of MPR","timeFrame":"Week 0 to year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":"40.9"},{"groupId":"OG001","value":"55.8","spread":"41.2"}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycemic Episodes Leading to an Inpatient Admission or Emergency Room (ER) Encounter From Baseline to Year 2","description":"Number of hypoglycemic episodes leading to an inpatient admission or emergency room (ER) encounter from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"644"},{"groupId":"OG001","value":"634"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc), Total Treatment Satisfaction Score Measured at Year 1","description":"DTSQc total treatment satisfaction score measured at year 1 is presented. The DTSQc provides a measure of how satisfied participants are with their current diabetes treatment compared with previous treatment. It consists of 8 questions, which are to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change. Six questions are summed to produce a total treatment satisfaction score. The remaining two questions concern perceived frequency of hyperglycemia and perceived frequency of hypoglycemia, respectively. The DTSQc total treatment satisfaction score ranges from -18 to +18, with higher scores associated with greater treatment satisfaction.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for DTSQ at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"460"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"5.28"},{"groupId":"OG001","value":"12.8","spread":"5.82"}]}]}]},{"type":"SECONDARY","title":"DTSQc, Total Treatment Satisfaction Score Measured at Year 2","description":"DTSQc total treatment satisfaction score measured at year 2 is presented. The DTSQc provides a measure of how satisfied participants are with their current diabetes treatment compared with previous treatment. It consists of 8 questions, which are to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change. Six questions are summed to produce a total treatment satisfaction score. The remaining two questions concern perceived frequency of hyperglycemia and perceived frequency of hypoglycemia, respectively. The DTSQc total treatment satisfaction score ranges from -18 to +18, with higher scores associated with greater treatment satisfaction.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for DTSQ at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"388"},{"groupId":"OG001","value":"380"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"6.24"},{"groupId":"OG001","value":"12.2","spread":"5.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 12-Item Version 2 Survey (SF-12 v2), Physical Component Summary (PCS-12) Score at Year 1","description":"Change from baseline in SF-12 v2, PCS-12 score at year 1 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for SF-12 at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"449"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"8.20"},{"groupId":"OG001","value":"2.3","spread":"7.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-12 v2, PCS-12 Score at Year 2","description":"Change from baseline in SF-12 v2, PCS-12 score at year 2 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for SF-12 at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"376"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"8.68"},{"groupId":"OG001","value":"2.4","spread":"7.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-12 v2, Mental Component Summary (MCS-12) Score at Year 1","description":"Change from baseline in SF-12 v2, MCS-12 score at year 1 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: PCS Score and MCS Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for SF-12 at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"449"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"8.54"},{"groupId":"OG001","value":"1.1","spread":"8.17"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-12 v2, MCS-12 Score at Year 2","description":"Change from baseline in SF-12 v2, MCS-12 score at year 2 is presented. The SF-12 v2 is a 12-item generic health-related quality of life measure that assesses physical and mental functioning. The items were scored using the scoring software. It contains two summary scores: PCS Score and MCS Score. The scores are norm-scored such that the scores range from 0-100 with a mean of 50 and standard deviation of 10. A higher score is associated with better quality of life and a lower score, poorer quality of life.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for SF-12 at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"376"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"8.43"},{"groupId":"OG001","value":"0.2","spread":"9.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment, General Health Questionnaire (WPAI-GH) Absenteeism (Work Time Missed) Score at Year 1","description":"Change from baseline in WPAI-GH Absenteeism (work time missed) score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"241"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"21.39"},{"groupId":"OG001","value":"0.9","spread":"14.39"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Absenteeism (Work Time Missed) Score at Year 2","description":"Change from baseline in WPAI-GH Absenteeism (work time missed) score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"22.86"},{"groupId":"OG001","value":"0.0","spread":"14.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) Score at Year 1","description":"Change from baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"24.31"},{"groupId":"OG001","value":"-4.5","spread":"22.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) Score at Year 2","description":"Change from baseline in WPAI-GH Presenteeism (Impairment at Work/Reduced On-the-job Effectiveness) score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"24.30"},{"groupId":"OG001","value":"-3.8","spread":"24.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Work Productivity Loss (Overall Work Impairment/Absenteeism Plus Presenteeism) Score at Year 1","description":"Change from baseline in WPAI-GH work productivity loss (overall work impairment/absenteeism plus presenteeism) score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"25.64"},{"groupId":"OG001","value":"-4.5","spread":"24.79"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Work Productivity Loss (Overall Work Impairment/Absenteeism Plus Presenteeism) Score at Year 2","description":"Change from baseline in WPAI-GH work productivity loss (overall work impairment/absenteeism plus presenteeism) score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"25.18"},{"groupId":"OG001","value":"-4.0","spread":"25.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Activity Impairment Score at Year 1","description":"Change from baseline in WPAI-GH activity impairment score at year 1 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"445"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"27.91"},{"groupId":"OG001","value":"-3.7","spread":"27.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI-GH Activity Impairment Score at Year 2","description":"Change from baseline in WPAI-GH activity impairment score at year 2 is presented. The WPAI-GH yields four types of scores: Absenteeism (work time missed), Presenteesism (impairment at work/reduced on-the-job effectiveness), Work productivity loss (overall work impairment/absenteeism plus presenteeism), and Activity Impairment. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes (percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health, percent activity impairment due to health).","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for WPAI-GH at the dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"375"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"27.51"},{"groupId":"OG001","value":"-3.1","spread":"28.03"}]}]}]},{"type":"SECONDARY","title":"All Cause Healthcare Resource Utilization (HCRU): Mean Number of Inpatient Admissions Per Participant From Baseline to Year 2","description":"All cause healthcare resource utilization - mean number of inpatient admissions per participant from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"inpatient admissions","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.55"},{"groupId":"OG001","value":"0.25","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Mean Cumulative Length of Stay for Inpatient Admissions Per Participant From Baseline to Year 2","description":"All cause HCRU - mean cumulative length of stay for inpatient admissions per participant from baseline to year 2 is presented. Cumulative inpatient length of stay is the sum of the length of stay of all inpatient admissions a participant experiences from baseline to year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not. It is only calculated for participants with at least one inpatient admission.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"3.4"},{"groupId":"OG001","value":"7.7","spread":"12.1"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Mean Number of Emergency Room (ER) Encounters Per Participant From Baseline to Year 2","description":"All cause HCRU - mean number of emergency room (ER) encounters per participant from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ER encounters","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"2.01"},{"groupId":"OG001","value":"0.29","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Mean Number of Outpatient Encounters Per Participant From Baseline to Year 2","description":"All cause HCRU - mean number of outpatient encounters per participant from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"outpatient encounters","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":"17.7"},{"groupId":"OG001","value":"16.5","spread":"13.2"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Mean Number of Medication Visits Per Participant From Baseline to Year 2","description":"All cause HCRU - mean number of medication visits per participant from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"medication visits","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"43.1"},{"groupId":"OG001","value":"2.9","spread":"5.2"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Number of Participants With Inpatient Admission (Yes/No) From Baseline to Year 2","description":"All cause HCRU - number of participants with inpatient admission from baseline to year 2 is presented. Yes: number of participants who experienced inpatient admission; no: number of participants who did not experience inpatient admission.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"86"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Number of Participants With ER Encounter (Yes/No) From Baseline to Year 2","description":"All cause HCRU - number of participants with ER encounter from baseline to year 2 is presented. Yes: number of participants who experienced ER Encounter; no: number of participants who did not experience ER Encounter.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"21"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"81"}]}]}]},{"type":"SECONDARY","title":"All Cause HCRU: Number of Participants With Outpatient Encounter (Yes/No) From Baseline to Year 2","description":"All cause HCRU - number of participants with outpatient encounter from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code. Yes: number of participants who experienced outpatient encounter; no: number of participants who did not experience outpatient encounter.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"101"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Mean Number of Diabetes Related Inpatient Admissions Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related inpatient admissions per participant from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"inpatient admissions","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.37"},{"groupId":"OG001","value":"0.19","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Mean Cumulative Length of Stay for Diabetes Related Inpatient Admissions Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean cumulative length of stay for diabetes related inpatient admissions per participant from baseline to year 2 is presented. Cumulative inpatient length of stay is the sum of the length of stay of all diabetes related inpatient admissions a participant experiences from baseline to year 2.","populationDescription":"FAS: all randomized participants analyzed according to treatment group they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for the outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug/not. It is only calculated for participants with at least 1 diabetes related inpatient admission.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.9"},{"groupId":"OG001","value":"8.9","spread":"12.1"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Mean Number of Diabetes Related ER Encounters Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related ER encounters per participant from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ER encounters","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"1.49"},{"groupId":"OG001","value":"0.17","spread":"0.47"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Mean Number of Diabetes Related Outpatient Encounters Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related outpatient encounters per participant from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"outpatient encounters","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"12.9"},{"groupId":"OG001","value":"8.1","spread":"5.8"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Mean Number of Diabetes Related Medication Visits Per Participant From Baseline to Year 2","description":"Diabetes related HCRU - mean number of diabetes related medication visits per participant from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"medication visits","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.8"},{"groupId":"OG001","value":"1.1","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Number of Participants With Diabetes Related Inpatient Admission (Yes/No) From Baseline to Year 2","description":"Diabeted related HCRU - number of participants with diabetes related inpatient admission from baseline to year 2 is presented. Yes: number of participants who experienced diabetes related inpatient admission; no: number of participants who did not experience diabetes related inpatient admission.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"90"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Number of Participants With Diabetes Related ER Encounter (Yes/No) From Baseline to Year 2","description":"Diabeted related HCRU - number of participants with diabeted related ER encounter from baseline to year 2 is presented. Yes: number of participants who experienced diabeted related ER encounter; no: number of participants who did not experience diabeted related ER encounter.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"89"}]}]}]},{"type":"SECONDARY","title":"Diabetes Related HCRU: Number of Participants With Diabetes Related Outpatient Encounter (Yes/No) From Baseline to Year 2","description":"Diabeted related HCRU - number of participants with diabeted related outpatient encounter from baseline to year 2 is presented. Physician outpatient office visit is defined by a medical claim with outpatient place of service and an evaluation and management code. Yes: number of participants who experienced diabeted related outpatient encounter; no: number of participants who did not experience diabeted related outpatient encounter.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure. Analysis is based only on participants with available data for diabetes related HCRU at dedicated study visit including measurements irrespective of whether participants discontinued study drug or not.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline (less than or equal to 4 weeks prior to the randomization at week 0) to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"97"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Attained Individualized HbA1c Target at Year 2 (Yes/No)","description":"Number of participants who attained individualized HbA1c target at year 2 is presented. Study physicians set and documented an individualized HbA1c target for participants prior to randomization based on their clinical judgement and knowledge of the participant. Yes: number of participants who achieved individualized HbA1c target attained at year 2; No: number of participants who did not achieve individualized HbA1c target attained at year 2","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"129"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"245"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) or At Least 1% Point Improvement in HbA1c Compared to Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) or at least 1% point improvement in HbA1c compared to baseline at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 2; No: number of participants who did not achieve HbA1c less than 7.0% or at least 1% point improvement in HbA1c compared to baseline at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"373"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"274"},{"groupId":"OG001","value":"228"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"145"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1 is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 1.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"430"},{"groupId":"OG001","value":"462"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"344"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"118"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2 is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"293"},{"groupId":"OG001","value":"271"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"103"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) and No Further Antidiabetic Medication Intensification After Randomization at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 1; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 1.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"430"},{"groupId":"OG001","value":"462"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"206"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"254"}]}]},{"title":"Data missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) and No Further Antidiabetic Medication Intensification After Randomization at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 2; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) and no further antidiabetic medication intensification after randomization at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"373"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"135"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"238"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c target attainment per HEDIS criteria (less than 8.0% if age ≥ 65 years or with defined comorbidities, otherwise less than 7.0%) at year 2 is presented. Yes: Number of participants who achieved HbA1c target attainment per HEDIS criteria at year 2; No: Number of participants who did not achieve HbA1c target attainment per HEDIS criteria at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"52"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"29"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"23"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) at Year 1 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"122"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"80"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) at Year 2 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"28"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"70"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 1 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 1 in participants with HbA1c \\>9.0% at baseline","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"122"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"67"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"55"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 8.0% (64 mmol/Mol) at Year 2 in Participants With HbA1c >9.0% at Baseline (Yes/No)","description":"Number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline is presented. Yes: number of participants who achieved HbA1c less than 8.0% (64 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline; No: number of participants who did not achieve HbA1c less than 8.0% (64 mmol/mol) at year 2 in participants with HbA1c \\>9.0% at baseline.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"53"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Body Weight From Baseline to Year 2","description":"Percentage change in body weight from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change in body weight","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.47","spread":"12.204"},{"groupId":"OG001","value":"-2.68","spread":"7.988"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (in Pounds) From Baseline to Year 2","description":"Change in body weight (in pounds) from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"lbs","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":"24.65"},{"groupId":"OG001","value":"-6.8","spread":"18.54"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Year 2","description":"Change in SBP from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"388"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"17.03"},{"groupId":"OG001","value":"-2.8","spread":"16.91"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure (DBP) From Baseline to Year 2","description":"Change in DBP from baseline to year 2 is presented.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Baseline (less than or equal to 4 weeks prior to the randomization at week 0), year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"388"},{"groupId":"OG001","value":"386"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"10.58"},{"groupId":"OG001","value":"-1.4","spread":"9.92"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Reported Hypoglycemia Leading to Inpatient Admission or ER Encounter During Year 1 (Yes/No)","description":"Number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 1 is presented. Yes: number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 1; No: number of participants who did not report hypoglycemia leading to inpatient admission or ER encounter during year 1.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0 to year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"644"},{"groupId":"OG001","value":"634"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"644"},{"groupId":"OG001","value":"634"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Reported Hypoglycemia Leading to Inpatient Admission or ER Encounter During Year 2 (Yes/No)","description":"Number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 2 is presented. Yes: number of participants who reported hypoglycemia leading to inpatient admission or ER encounter during year 2; No: number of participants who did not report hypoglycemia leading to inpatient admission or ER encounter during year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0 to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"644"},{"groupId":"OG001","value":"634"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"643"},{"groupId":"OG001","value":"633"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and Body Weight Loss of ≥ 5% Versus Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 1; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 1","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"426"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"68"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"358"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absolute HbA1c Reduction of ≥ 0.5% Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and a Body Weight Loss of ≥ 5% Versus Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 1 is presented. Yes: number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 1; No: number of participants who did not achieve absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 1.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"425"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"79"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"346"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and Body Weight Loss of ≥ 5% Versus Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 2; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and body weight loss of ≥ 5% versus baseline at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"349"},{"groupId":"OG001","value":"352"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"76"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"276"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absolute HbA1c Reduction of ≥ 0.5% Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and a Body Weight Loss of ≥ 5% Versus Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 2 is presented. Yes: number of participants who achieved absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 2; No: number of participants who did not achieve absolute HbA1c reduction of ≥ 0.5% without experiencing hypoglycemia leading to inpatient admission or ER encounter and a body weight loss of ≥ 5% versus baseline at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"349"},{"groupId":"OG001","value":"351"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"89"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"262"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and No Body Weight Gain Versus Baseline at Year 1 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 1 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 1; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 1.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 1","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"426"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"159"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"267"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0% (53 mmol/Mol) Without Experiencing Hypoglycemia Leading to Inpatient Admission or ER Encounter and No Body Weight Gain Versus Baseline at Year 2 (Yes/No)","description":"Number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 2 is presented. Yes: number of participants who achieved HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 2; No: number of participants who did not achieve HbA1c less than 7.0% (53 mmol/mol) without experiencing hypoglycemia leading to inpatient admission or ER encounter and no body weight gain versus baseline at year 2.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"349"},{"groupId":"OG001","value":"352"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"118"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"234"}]}]}]},{"type":"SECONDARY","title":"Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence For The Two Years of The Study","description":"Percentage of MPR for study drug medication adherence for the two years of the study is presented. Medication adherence referred to a participant's conformance to the provider's recommendation with respect to timing, dosage, and frequency of medication taken during the prescribed length of time. The MPR was used to assess adherence. MPR was calculated as follows: MPR (%) = Sum of days supply for all prescription fills\\*100/Total number of days in time period. MPR was capped at 100%. MPR was calculated from pharmacy claims data and irrespective of adherence to randomized treatment or changes to antidiabetic treatment.","populationDescription":"FAS included all randomized participants analyzed according to the treatment group to which they were assigned at randomization. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of MPR","timeFrame":"Week 0 to year 2","groups":[{"id":"OG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."},{"id":"OG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":"40.5"},{"groupId":"OG001","value":"55.7","spread":"38.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to year 2 (week 104)","description":"An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product or medical device, which does not necessarily have to have a causal relationship to the product or device. The safety population includes all randomized patients initiated on study drug.","eventGroups":[{"id":"EG000","title":"Semaglutide","description":"Participants received semaglutide subcutaneous (s.c.) injection once weekly in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants.","deathsNumAffected":9,"deathsNumAtRisk":634,"seriousNumAffected":38,"seriousNumAtRisk":634,"otherNumAffected":0,"otherNumAtRisk":634},{"id":"EG001","title":"Standard of Care","description":"Participants received standard of care (any commercially available oral or injectable antidiabetic medication, excluding semaglutide) in addition to up to 2 oral antidiabetic medications as treatment intensification for 2 years. Medication dose and dose escalation was at the discretion of the study physician according to routine practice for medications for glycemic control in participants.","deathsNumAffected":9,"deathsNumAtRisk":621,"seriousNumAffected":39,"seriousNumAtRisk":621,"otherNumAffected":0,"otherNumAtRisk":621}],"seriousEvents":[{"term":"Coronavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":634},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":621}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Abdominal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Disseminated varicella zoster vaccine virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Osteomyelitis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":621}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":621}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":621}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":621}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Coronary artery dissection","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Breast cancer recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Colon cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Gastroenteropancreatic neuroendocrine tumour disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Intraductal proliferative breast lesion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Lung carcinoma cell type unspecified stage III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Myelodysplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Small cell lung cancer extensive stage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Uterine cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Acute haemorrhagic ulcerative colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Pancreatic cyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":621}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":621}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Accidental death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Abnormal loss of weight","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Diabetic nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":621}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Myasthenia gravis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Visual field defect","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Subarachnoid haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Polymyalgia rheumatica","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Breast dysplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Acinar cell carcinoma of pancreas","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Adenocarcinoma pancreas","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Apparent death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":634},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":621}]},{"term":"Hospitalisation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":634},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":621}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Office (2834)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-12-05","uploadDate":"2024-06-07T06:44","filename":"Prot_002.pdf","size":2456193},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-10-26","uploadDate":"2024-06-07T06:44","filename":"SAP_003.pdf","size":2385750}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591245","term":"semaglutide"},{"id":"D059039","term":"Standard of Care"}],"ancestors":[{"id":"D019984","term":"Quality Indicators, Health Care"},{"id":"D011787","term":"Quality of Health Care"},{"id":"D006298","term":"Health Services Administration"},{"id":"D017530","term":"Health Care Quality, Access, and Evaluation"}]}},"hasResults":true}